MARKER THERAPEUTICS, INC. CONSULTING SERVICES AGREEMENTConsulting Services Agreement • March 15th, 2019 • Marker Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Consulting Services Agreement (“Agreement”) is hereby made and entered into this 19th day of October, 2018 (“Effective Date”) by and between Marker Therapeutics, Inc., a Delaware corporation, having an address at 3200 Southwest Freeway, Suite 2240, Houston, Texas 77027 and its subsidiaries (“Marker” or the “Company”), and Ann Leen, having an address at 2727 Drexel Drive, Houston, Texas 77027 (“Consultant”). Marker and Consultant are referred to herein collectively as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 15th, 2019 • Marker Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Exclusive License Agreement (hereinafter called this “Agreement”), to be effective as of the 16th day of March, 2018 (hereinafter called the “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called “BCM”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and Marker Therapeutics, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 33 5th Avenue N.W., New Brighton, Minnesota (hereinafter, referred to as “LICENSEE”).
SPONSORED RESEARCH CONTRACTSponsored Research Contract • March 15th, 2019 • Marker Therapeutics, Inc. • Pharmaceutical preparations • Texas
THIS CONTRACT, effective the 16th day of November, 2018 (hereinafter the “Effective Date”), is entered into by and between Baylor College of Medicine (hereinafter “Baylor”) and Marker Therapeutics, Inc., a Delaware corporation, with principal offices located at 3200 Southwest Freeway Suite 2240, Houston, TX 77027 (hereinafter “Sponsor”), governing research to be conducted at Baylor in the laboratory of Dr. Juan Vera (hereinafter “Principal Investigator”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 15th, 2019 • Marker Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made and entered into as of October 17, 2018 by and between Marker Therapeutics, Inc., a Delaware corporation (the “Company”) and [_________] (“Indemnitee”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 15th, 2019 • Marker Therapeutics, Inc. • Pharmaceutical preparations • Texas
THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made on this 14th day of March, 2019, by and between Marker Therapeutics, Inc., a Delaware corporation (formerly known as TapImmune Inc. the “Company”), and Peter L. Hoang, an individual (the “Executive”), and amends that certain Employment Agreement between the Company and the Executive, dated September 22, 2017 (the “Employment Agreement”).
